INSM - Latest News

Insmed Incorporated (INSM), operates in Healthcare / Biotechnology, trades on NASDAQ.

Market capitalization stands near $24.74B. Beta to the broader market is 0.82.

The article list below shows the most recent INSM headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent INSM Headlines

3 Healthcare Stocks Showing Why the Sector Still Has Momentum

marketbeat.com - Sep 28, 2026

The healthcare sector has performed fairly well so far in 2026 due to several factors: GLP-1 medications continue to drive new business and interest,

FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce

zacks.com - Sep 22, 2026

INSM's Arikayce label expansion gets FDA priority review, potentially broadening its use in newly diagnosed MAC lung disease.

Insmed: Expensive Stock, But Discount To Recent Highs Makes Bull Case

seekingalpha.com - Sep 22, 2026

Insmed is rated Buy, driven by Brinsupri's blockbuster launch and strong TPIP Phase 2b data. Brinsupri generated $517m in 1H 2026, faces minimal comp

FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027

prnewswire.com - Sep 21, 2026

—sNDA Under Review for Full Approval Is Based on Positive Results From Phase 3b ENCORE Study— —Full Approval Could Bring ARIKAYCE to Patients Earlier

Insmed Expands Community Impact During Fifth Annual Global Day of Good

prnewswire.com - Sep 16, 2026

Company-wide day of service brings together more than 1,350 employees to support over 50 organizations throughout the U. S.

How News Affects INSM Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track INSM's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked INSM news questions

What is the latest INSM news headline?

The most recent INSM headline (Sep 28, 2026) is "3 Healthcare Stocks Showing Why the Sector Still Has Momentum". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.

How fresh is the INSM news on this page?

News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.

What INSM news moves options pricing?

Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.

How can I track unusual INSM options activity related to news?

Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.